What is melanoma? Melanoma is cancer arising in melanocytes, the pigment-producing cells. It can invade nearby tissue and spread elsewhere, so a new suspicious mark or changing mole needs clinical assessment. NCI melanoma and mole distinctions.
Confidence: high for the need for tissue diagnosis and care based on the actual disease extent; this guide describes specialist pathways without assigning an independently cleared efficacy score to a medicine. Its main scope is skin melanoma. Eye and mucosal melanoma require their own specialist assessment.
- Melanoma is pigment-cell cancer; a changing lesion needs assessment rather than image-based diagnosis.
- New lesions, palms, soles and under-nail changes matter across skin tones.
- A biopsy identifies the cancer; further tests assess its depth and spread.
- Surgery and selected oncology treatments depend on actual disease extent and health.
- Sun protection and good nutrition support care but do not treat an existing melanoma.
Table of contents
- Evidence summary
- What melanoma is: pigment-cell cancer, not every mole
- Symptoms: evolving marks, nails, palms and soles
- Diagnosis and staging: a biopsy answers a different question from a scan
- Treatment: surgery, selected medicines and the purpose of care
- Sun protection and lifestyle: prevention does not treat a melanoma
- Sentinel-node assessment and treatment risks
- Interactions: the actual prescription and ingredient list matter
- Mole checks, screening and who needs individual advice
- Clinician-led follow-up: keep the diagnosis and care plan together
- Supplements, animal research and clinical trials
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Can a mark diagnose melanoma? | Current NHS symptom and biopsy education. | Public website policy; exact expert/study interests unclosed. | Examination and tissue assessment, not a home score. |
| How is spread assessed? | Selected NCI staging and sentinel-node context. | Federal/gift routes; original study and member ties unclosed. | Individual staging; no automatic node-biopsy rule. |
| What are treatment options? | NHS July 2026 and selected NCI pathways. | Clinical education is not financially cleared trial evidence. | Attributed care families; no independent product-effect estimate. |
| Can supplements replace treatment? | NCI diet, interaction and prevention limits. | Specific product trials not independently cleared. | No replacement benefit established; check ingredients. |
What melanoma is: pigment-cell cancer, not every mole
Melanoma is distinct from basal-cell and squamous-cell skin cancers. It can spread, and treatment depends on its location, disease extent and the person’s health. The term “skin cancer” alone is therefore insufficient when discussing a biopsy result. NHS melanoma overview.
Common and atypical moles are not automatically cancer. Melanoma can start in an existing mole, but it more often appears in previously normal-looking skin. Most moles are not routinely removed simply to prevent melanoma. A suspicious change requires assessment rather than a blanket rule to remove every mole. NCI mole-versus-melanoma explanation.
Symptoms: evolving marks, nails, palms and soles
A new mole, changing size, shape or colour, uneven edges, multiple colours, bleeding, itching or crusting can be warning signs. A persistent unusual mark on a palm or sole, or unexplained darkening under a nail, also warrants assessment. Melanoma may be smaller than the size illustrated in common checklists. Current NHS symptom guidance.
Describe what changed and when, including an area that is difficult to see. A photograph may help explain change to the clinician; it cannot confirm pathology. Do not dismiss a lesion because it does not match an online image. The aim is to arrange an appropriate examination, not to diagnose cancer from colour or diameter alone.
A clinician may use a photograph for specialist review and arrange an urgent referral if cancer is suspected. Referral means further investigation is needed; it does not mean the diagnosis is already confirmed. Referral context.
Diagnosis and staging: a biopsy answers a different question from a scan
Specialists examine the skin and may use magnification. An excision biopsy removes the suspicious lesion with a small surrounding area for laboratory examination. After a melanoma diagnosis, selected imaging, blood tests or lymph-node investigations may establish depth and spread. These results inform the treatment plan. NHS diagnostic pathway.
NCI distinguishes tumour thickness, ulceration and involvement of lymph nodes or distant sites when describing disease extent and prognosis. Stage is not determined by the diameter visible in a photograph. Selected melanoma staging context.
Ask for the pathology diagnosis, what further information is needed and who will communicate the results. This guide supplies no home staging score, biopsy technique or surgical-margin measurement. If results are delayed, contact the service for an update rather than interpreting the delay as either reassuring or ominous.
Treatment: surgery, selected medicines and the purpose of care
Surgery is the main treatment, particularly for early melanoma. Selected patients may receive radiotherapy, immunotherapy or targeted medicines. A tumour sample may be tested for gene changes before targeted treatment. The choice depends on the actual cancer and health circumstances, not simply on which treatment sounds newest. July 2026 NHS treatment overview.
NCI describes wide local excision and additional options for disease that cannot be removed or has recurred. Oncolytic-virus therapy is also a selected treatment category; investigational vaccine approaches should not be mistaken for a routine prescription. Selected treatment categories.
When cure is not possible, symptom-control and palliative teams can help with comfort and support. Concerning symptoms or treatment effects should be reported without waiting for the next scheduled visit. Support and between-visit care.
Clarify whether proposed care aims to remove local disease, reduce recurrence risk, control established spread or relieve symptoms. These goals are different. This review does not rank products or adopt a numerical survival benefit from sponsored trials cited inside an institutional summary.
Sun protection and lifestyle: prevention does not treat a melanoma
UV exposure from sunlight and tanning devices is a major cause of skin melanoma. Risk also relates to a history of sunburns, many moles, skin that burns easily and personal or family skin-cancer history. People with brown or black skin can still develop melanoma, including under nails and on palms or soles. NHS risk context.
The NHS advises reducing intense sun exposure, using protective clothing and appropriate broad UV protection, and reapplying sunscreen. Sun protection should accompany care; it does not remove an existing tumour. Local UV conditions matter, so UK clock times are not universal worldwide rules. Sun-protection guidance.
NCI’s prevention summary distinguishes practical sun-protection advice from uncertainty about specific cancer-endpoint studies. This review offers no numerical guarantee of melanoma prevention or claim that a particular sunscreen brand has independently established superiority. Prevention-evidence boundary.
Sentinel-node assessment and treatment risks
A sentinel-node biopsy samples a first-draining lymph node to look for spread and help stage selected melanomas. It is not required for every lesion. Possible harms include swelling or lymphoedema, pain, infection, numbness, dye reactions and false-negative results. Ask what information the procedure would add in the actual case. NCI sentinel-node role and risks.
Immunotherapy can affect healthy tissues as well as cancer. Side effects may begin during or after treatment; they can include diarrhoea, breathing problems or organ inflammation. Obtain the team’s written warning signs and contact instructions. Severe breathing difficulty or a rapidly serious reaction needs emergency assessment. Selected immunotherapy safety context.
The treatment team should explain the relevant procedure and medicine risks before consent. A side-effect list cannot predict whether a particular person will experience them. This article gives no reassurance based on a rare-event percentage and no instruction to suppress a new symptom with a supplement.
Interactions: the actual prescription and ingredient list matter
Foods and concentrated supplements can alter anticancer-drug exposure. NCI discusses St John’s wort and grapefruit among examples; these interactions are drug-specific. Give the oncology pharmacist the actual medicine list and ingredient labels rather than relying on a generic “natural” safety claim. Selected food and supplement interactions.
Include nonprescription tablets, teas, extracts, skin products and medicines supplied by another clinic. Tell the team about planned surgery and any medicine used for another condition. This guide does not prescribe a universal food ban, authorize stopping a medicine or substitute a different product because it has similar marketing. Compatibility has to be checked against the actual treatment.
Mole checks, screening and who needs individual advice
Screening looks for cancer before symptoms; assessment of a changing lesion is a diagnostic question. Screening can produce false-positive or false-negative results and biopsy-related harms. NCI says lesion-assessment apps require further large-scale study. An app’s reassurance should not delay evaluation of a concerning change. Screening and app limitations.
People with a previous melanoma, substantial family history or several atypical lesions should discuss a personalized skin-review plan. A friend helping inspect a hard-to-see area does not replace clinical assessment. Eye, nail or genital lesions need an appropriately trained service rather than assumptions drawn from a usual sun-exposed skin example.
Clinician-led follow-up: keep the diagnosis and care plan together
After cancer treatment, NCI describes a written treatment summary and follow-up plan, including pathology, procedures, medicines, late-effect concerns and contact details. Report new problems between visits; they may relate to recurrence, treatment or another illness. The schedule should reflect the actual disease and care received. Follow-up-care planning.
For melanoma, keep the lesion location and pathology record available alongside any lymph-node findings. Ask who checks the skin, who reviews medicine effects and who receives scan results. This article gives no universal scan interval, dose, missed-dose instruction or rule to stop follow-up after a normal visit. A clear point of contact makes a new concern easier to assess promptly.
Supplements, animal research and clinical trials
No independently established supplement or diet replacement for melanoma treatment was identified in this review. NCI distinguishes nutrition support from claims that vitamins, herbs or restrictive eating cure cancer or stop its return. Discuss a proposed supplement or diet with the oncology team, especially when appetite or weight is changing. Nutrition and supplement limits.
A melanoma-cell experiment or animal tumour response does not establish a patient benefit. Human conclusions need meaningful outcomes, an appropriate comparator, follow-up, harms and a full funding and author-interest assessment. A laboratory mechanism does not select a personal treatment.
Clinical trials study prevention, diagnosis, treatments and ways to manage cancer problems. A trial is a research option with its own eligibility and consent process; listing it does not establish superiority or suitability. Ask which aspects remain experimental and who funds the original study. Clinical-trial role.
Funding and source roles
Research funding at a glance
21 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS melanoma definition | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 15 July 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS melanoma symptoms | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 15 July 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS melanoma causes | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 15 July 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS melanoma tests and next steps | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 15 July 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS melanoma treatment | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 15 July 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NCI melanoma patient PDQ | Derived professional version and named lead; separate January/February 2026 disclosure records consulting/advisory interests. NCI fiscal routes are in dedicated profiles. Later relationships are not payment attribution to this page; source-trial contracts unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 3 derived source with disclosed professional reviewer relationships. | C, provisional — actual patient derivation and professional lead credit read. Khan’s later relevant interests and incompletely public member/study finances limit independence; no page payment or product efficacy inferred. |
| NCI common and atypical moles | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; Institutional mission and unclosed page/contributor interests remain. |
| NCI sentinel-node biopsy | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; Institutional mission and unclosed page/contributor interests remain. |
| NCI skin-cancer screening patient PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; PDQ board-specific interests are not fully published. Not a treatment guideline. |
| NCI skin-cancer prevention patient PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; updated 16 May 2025; PDQ board-specific interests are not fully published. Not a treatment guideline. |
| NCI immunotherapy side effects | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; reviewed 16 February 2023; Institutional mission and unclosed page/contributor interests remain. |
| NCI diets and supplements | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; posted 30 October 2024; Institutional mission and unclosed page/contributor interests remain. |
| NCI food and supplement interactions PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; updated 25 April 2024; PDQ board-specific interests are not fully published. Not a treatment guideline. |
| NCI follow-up medical care | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; Institutional mission and unclosed page/contributor interests remain. |
| NCI clinical-trial overview | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; Institutional mission and unclosed page/contributor interests remain. |
| NCI budget and appropriations, May 2026 | Congressional funding through HHS/NIH. Enacted appropriations and future requests differ; no disease-page amount assigned. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual budget process and dated body read; fiscal accountability, budget priorities and missing page allocation. |
| NCI Gift Fund and contribution routes, August 2025 | Public gifts/Gift Fund and Breast Cancer Research Stamp route separate from Congress. Named page donors and complete accepted receipts unclosed. | United States; 9000 Rockville Pike, Bethesda, Maryland; federal NCI. | Tier 3 institutional financial self-report. | B, provisional — actual contribution and headquarters text read; no named donor control or page sponsorship inferred. |
| NCI PDQ editorial boards, November 2022 | NCI support; non-government member honoraria/travel expenses. Declarations and recusal required; specific conflicts not publicly required. | United States; NCI, Bethesda, with international board contributors. | Tier 3 institutional process and payment self-report. | B, provisional — actual dated policy read; editorial independence does not clear member interests or sponsored underlying trials. |
| NHS national content policy, October 2022 | DHSC funding; policy states no advertising or corporate sponsorship. Full page/expert receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B, provisional — actual funding/accuracy policy read; next review due October 2025 passed. Not a provider-trust accounts profile. |
| NCI professional melanoma PDQ: lead reviewer attribution | Separate institutional fiscal route; actual professional page credits Shaheer A. Khan. January/February 2026 declaration reports advisory/consulting ties. Exact page remuneration and underlying-study chains unclosed. | United States; NCI/NIH/HHS, Bethesda; page credit lists Columbia University Irving Medical Center. | Tier 3 source with disclosed professional-reviewer relationships. | C, provisional — actual professional credit and summary-role passages read; dated external commercial ties not assigned as payment for the May 2025 page. Full trial/member finances unclosed. |
| Shaheer A. Khan January/February 2026 financial disclosure | Actual three-page publisher original identifies advisory/consulting relationships with Regeneron, Ideaya Biosciences, Replimune and Immunocore. Interview/article financing and complete amounts unclosed; not payment attribution to May 2025 NCI skin page. | United States; disclosed author at Zucker School of Medicine, Hofstra University, Hempstead, New York. Complete backer jurisdictions not traced here. | Tier 3 author with relevant commercial relationships; financial-only. | C, provisional — explicit dated declaration helps accuracy. Full remuneration, publisher backers and page-period allocation unclosed; no clinical effect adopted. |
Frequently asked questions
Can melanoma appear without an old mole? Yes. NCI explains that it more often begins in normal-looking skin than in a pre-existing mole. A new changing lesion also matters. Mole distinctions.
Can people with darker skin get melanoma? Yes. The NHS includes palms, soles and under-nail lesions in its warning context. Skin colour does not exclude the diagnosis. Symptom guidance.
Does every melanoma need a sentinel-node biopsy? No universal rule is supplied here. Discuss whether the procedure will add useful staging information and its potential harms. Procedure context.
Is a clear skin photograph enough to rule it out? No. Clinical assessment and, when indicated, tissue examination answer the diagnostic question; apps and photographs are not pathology results.
Can supplements replace surgery or oncology care? This review establishes no independently cleared replacement benefit. Nutrition and symptom support should be coordinated with the actual care plan.
Sources and funding notes
Actual NHS melanoma bodies were reviewed 15 July 2026. Selected NCI staging, procedure, safety, screening, prevention and supportive-care originals were read; historical schedules, numerical stage cutoffs and product-effect estimates were excluded. Main scope is cutaneous melanoma, not a full ocular or mucosal treatment guide. The patient PDQ expressly derives from its professional version naming Shaheer A. Khan. His separate January/February 2026 declaration lists Regeneron, Ideaya Biosciences, Replimune and Immunocore advisory/consulting relationships; these later interests do not establish payment for the May 2025 pages. NCI fiscal routes remain separate from reviewer and original-trial interests. Complete underlying trial contracts and individual payment chains remain unresolved; editorial review does not remove sponsorship. Sources are concentrated in the United States and United Kingdom, and local access and licensing differ.
- NHS melanoma definition — Skin melanoma scope and care distinction.
- NHS melanoma symptoms — Changing lesions, nails/palms/soles and referral.
- NHS melanoma causes — UV risk and practical protection, not a brand effect estimate.
- NHS melanoma tests and next steps — Biopsy and selected staging tests.
- NHS melanoma treatment — Care categories, symptom support and follow-up.
- NCI melanoma patient PDQ — Selected staging and treatment categories; no product efficacy ranking.
- NCI common and atypical moles — Pigment-cell definition and distinctions from noncancerous moles.
- NCI sentinel-node biopsy — Procedure purpose and harms; no eligibility cutoff.
- NCI skin-cancer screening patient PDQ — Screening versus symptomatic diagnosis and app uncertainty.
- NCI skin-cancer prevention patient PDQ — Endpoint uncertainty separate from protection guidance.
- NCI immunotherapy side effects — Selected serious harm context, no incidence reassurance.
- NCI diets and supplements — Nutrition distinction and ingredient caution.
- NCI food and supplement interactions PDQ — Selected drug-specific interaction context.
- NCI follow-up medical care — Treatment summary and individualized follow-up.
- NCI clinical-trial overview — Research role, not individual trial efficacy.
- NCI budget and appropriations, May 2026 — Institutional appropriation route only.
- NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
- NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
- NHS national content policy, October 2022 — Website funding and editorial safeguards only.
- NCI professional melanoma PDQ: lead reviewer attribution — Selected named-lead and summary role only; no additional treatment claims.
- Shaheer A. Khan January/February 2026 financial disclosure — Financial declaration only; uveal-melanoma treatment claims not used.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.